Last reviewed · How we verify
NCT05230550
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
trial testing Somapacitan in Adult Growth Hormone Deficiency in 200 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 3 February 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 47 locations across Japan |
Drugs / interventions tested
- Somapacitan (SOMAPACITAN) — full drug profile →
Conditions studied
- Adult Growth Hormone Deficiency — all drugs for Adult Growth Hormone Deficiency →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
Eligibility, any sex, with Adult Growth Hormone Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Participants are invited to take part in this study because they have AGHD (only severe case). The purpose of this study is to assess long term safety and effectiveness of Sogroya® in patients with AGHD (only severe case) under normal clinical practice condition in Japan. Participants will get Sogroya® as prescribed by the study doctor. Participants will be in the study for about 2 to 5 years depending on when they take part in the study. Participants will be asked to fill in the quality of life questionnaires.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation.
Bidlingmaier M, Biller BMK, Clemmons D, Jørgensen JOL, et al · · 2022 · cited 9× · PMID 36619571 · DOI 10.3389/fendo.2022.1040046
Verify or expand the search:
- PubMed search for NCT05230550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Somapacitan
Trials testing the same drug.
- NCT06709040 — A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety I · enrolling by invitation
- NCT06109935 — Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Defic · enrolling by invitation
- NCT05718570 — A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Inform · enrolling by invitation
- NCT05723835 — A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 · Phase 3 · active not recruiting
- NCT05330325 — A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow · Phase 3 · active not recruiting
Other recruiting trials for Adult Growth Hormone Deficiency
Currently open trials in the same condition.
- NCT07016802 — A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) · Phase 1 · recruiting
- NCT04867317 — Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficien · Phase 3 · recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05230550 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05230550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing